CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...